1400742-18-8

Basic information

• Product Name: 1-(5-fluoropentyl)-N-(1-methyl-1-phenylethyl)-1H-indole-3-carboxamide
• CAS NO: 1400742-18-8
• Molecular Weight: 366.479
• Mol File: 1400742-18-8.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 1-(5-fluoropentyl)-N-(1-methyl-1-phenylethyl)-1H-indole-3-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(5-fluoropentyl)-N-(1-methyl-1-phenylethyl)-1H-indole-3-carboxamide(1400742-18-8)
• EPA Substance Registry System: 1-(5-fluoropentyl)-N-(1-methyl-1-phenylethyl)-1H-indole-3-carboxamide(1400742-18-8)

Safety Data

• Hazardous Substances Data: 1400742-18-8(Hazardous Substances Data)

Usage

Description

1-(5-fluoropentyl)-N-(1-methyl-1-phenylethyl)-1H-indole-3-carboxamide, also known as 5-fluoro CUMYL-PICA, is a derivative of the aminoalkylindole cannabinoid AM2201. It is an analog of CUMYL-PICA characterized by the addition of an alkyl-terminal fluorine atom. The physiological and toxicological properties of this compound are not known. This product is intended for forensic and research applications.

Uses

Used in Pharmaceutical Research:
1-(5-fluoropentyl)-N-(1-methyl-1-phenylethyl)-1H-indole-3-carboxamide is used as a research compound for studying the effects and interactions of cannabinoids with the human body, particularly the CB1 and CB2 receptors. Its application in this field aids in understanding the potential therapeutic uses of cannabinoids and their analogs.
Used in Forensic Applications:
In the forensic field, 1-(5-fluoropentyl)-N-(1-methyl-1-phenylethyl)-1H-indole-3-carboxamide is used for the identification and analysis of substances related to cannabinoid agonists. This helps in the detection and investigation of cases involving the use of such compounds.
Different applications in different industries are not provided in the materials. However, based on the information given, the primary uses of 1-(5-fluoropentyl)-N-(1-methyl-1-phenylethyl)-1H-indole-3-carboxamide are in pharmaceutical research and forensic applications.

Upstream product

• 1859218-30-6 N-fluoropentyl indole 
• 585-32-0 2-phenyl-2-propylamine 
• 1432794-98-3 1-(5-fluoropentyl)-1H-indole-3-carboxylic acid 
• 407-97-6 1-bromo-5-fluoropentane 
• 120-72-9 indole 

Relevant articles and documents

Exploring Stereochemical and Conformational Requirements at Cannabinoid Receptors for Synthetic Cannabinoids Related to SDB-006, 5F-SDB-006, CUMYL-PICA, and 5F-CUMYL-PICA

Synthetic cannabinoid receptor agonists (SCRAs) represent the most rapidly expanding class of new psychoactive substances (NPSs). Despite the prevalence and potency of recent chiral indole-3-carboxamide SCRAs, few pharmacological data are available regarding the enantiomeric bias of these NPSs toward human CB1 and CB2 receptors. A series of homochiral indole-3-carboxamides derived from (S)- and (R)-α-methylbenzylamine and featuring variation of the 1-alkyl substituent were prepared, pharmacologically evaluated, and compared to related achiral congeners derived from cumyl- and benzylamine. Competitive binding assays demonstrated that all analogues derived from either enantiomer of α-methylbenzylamine (14-17) showed affinities for CB1 (Ki = 47.9-813 nM) and CB2 (Ki = 47.9-347 nM) that were intermediate to that of the corresponding benzylic (10-13, CB1 Ki = 550 nM to >10 μM; CB2 Ki = 61.7 nM to >10 μM) and cumyl derivatives (6-9, CB1 Ki = 12.6-21.4 nM; CB2 Ki = 2.95-24.5 nM). In a fluorometric membrane potential assay, all α-methylbenzyl analogues (excluding 17) were potent, efficacious agonists of CB1 (EC50 = 32-464 nM; Emax = 89-104%) and low efficacy agonists of CB2 (EC50 = 54-500 nM; Emax = 52-77%), with comparable or greater potency than the benzyl analogues and much lower potency than the cumyl derivatives, consistent with binding trends. The relatively greater affinity and potency of (S)-14-17 compared to (R)-14-17 analogues at CB1 highlighted an enantiomeric bias for this series of SCRAs. Molecular dynamics simulations provided a conformational basis for the observed differences in agonist potency at CB1 pending benzylic substitution.